Zahraa Al-Hilli1, Grace Choong2, Michael G Keeney3, Daniel W Visscher3, James N Ingle4, Matthew P Goetz4, James W Jakub5. 1. Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. 3. Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA. 4. Department of Oncology, Mayo Clinic, Rochester, MN, USA. 5. Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. jakub.james@mayo.edu.
Abstract
OBJECTIVE: Metaplastic breast cancer (MetaBC) is a rare breast cancer subtype poorly responsive to systemic therapy in the metastatic setting with high recurrence rates in the adjuvant setting. However, limited data exist regarding response to neoadjuvant chemotherapy (NAC). We performed a single institutional study to assess the clinical and pathological complete response rates (pCR) of MetaBC to NAC. METHODS: Mayo Clinic Rochester patients with MetaBC treated with NAC were identified using the institutional medical index. Patient demographics, tumor characteristics, chemotherapy treatment, clinical and pathological response, and long-term outcomes were reviewed. Pathologic response was assessed by direct pathology review (n = 14) or review of outside surgical and pathology reports (n = 4). RESULTS: Women with MetaBC (n = 18) received NAC from January 1991 to June 2014. The mean age was 50 years (range 33-79) with a mean tumor size of 5.1 cm (range 2.3-11 cm) and 6/18 had pathologically confirmed lymph nodes prior to surgery. The majority (13/18; 72%) were estrogen receptor (ER), progesterone receptor (PR) and HER-2 negative (TNBC), and 1/18 (5.5%) was HER-2 positive. Five had BRCA testing and 2/5 were BRCA-2 positive. The chemotherapy regimens included anthracycline/cyclophosphamide (AC) (n = 1), AC/taxane (n = 3), AC/taxane/platinum (n = 8), taxane/platinum-based regimens (n = 4), taxane/cyclophosphamide (n = 1) and taxane/trastuzumab (n = 1). Five of 18 (28%) progressed on initial treatment including two who developed metastatic disease during NAC. The overall pCR rate was 2/18 (11%). CONCLUSION: MetaBC is poorly responsive to NAC, with a pCR rate (11%), that is lower than expected in a predominantly TNBC cohort. MetaBC patients should be considered for clinical trials testing new NAC regimens and in the absence of clinical trial enrollment, MetaBC patients with resectable disease should proceed directly to definitive operative management.
OBJECTIVE:Metaplastic breast cancer (MetaBC) is a rare breast cancer subtype poorly responsive to systemic therapy in the metastatic setting with high recurrence rates in the adjuvant setting. However, limited data exist regarding response to neoadjuvant chemotherapy (NAC). We performed a single institutional study to assess the clinical and pathological complete response rates (pCR) of MetaBC to NAC. METHODS:Mayo Clinic Rochester patients with MetaBC treated with NAC were identified using the institutional medical index. Patient demographics, tumor characteristics, chemotherapy treatment, clinical and pathological response, and long-term outcomes were reviewed. Pathologic response was assessed by direct pathology review (n = 14) or review of outside surgical and pathology reports (n = 4). RESULTS:Women with MetaBC (n = 18) received NAC from January 1991 to June 2014. The mean age was 50 years (range 33-79) with a mean tumor size of 5.1 cm (range 2.3-11 cm) and 6/18 had pathologically confirmed lymph nodes prior to surgery. The majority (13/18; 72%) were estrogen receptor (ER), progesterone receptor (PR) and HER-2 negative (TNBC), and 1/18 (5.5%) was HER-2 positive. Five had BRCA testing and 2/5 were BRCA-2 positive. The chemotherapy regimens included anthracycline/cyclophosphamide (AC) (n = 1), AC/taxane (n = 3), AC/taxane/platinum (n = 8), taxane/platinum-based regimens (n = 4), taxane/cyclophosphamide (n = 1) and taxane/trastuzumab (n = 1). Five of 18 (28%) progressed on initial treatment including two who developed metastatic disease during NAC. The overall pCR rate was 2/18 (11%). CONCLUSION:MetaBC is poorly responsive to NAC, with a pCR rate (11%), that is lower than expected in a predominantly TNBC cohort. MetaBCpatients should be considered for clinical trials testing new NAC regimens and in the absence of clinical trial enrollment, MetaBCpatients with resectable disease should proceed directly to definitive operative management.
Entities:
Keywords:
Metaplastic breast cancer; Neoadjuvant chemotherapy; Pathological and clinical outcomes
Authors: Clinton Yam; Nour Abuhadra; Ryan Sun; Beatriz E Adrada; Qing-Qing Ding; Jason B White; Elizabeth E Ravenberg; Alyson R Clayborn; Vicente Valero; Debu Tripathy; Senthilkumar Damodaran; Banu K Arun; Jennifer K Litton; Naoto T Ueno; Rashmi K Murthy; Bora Lim; Luis Baez; Xiaoxian Li; Aman U Buzdar; Gabriel N Hortobagyi; Alistair M Thompson; Elizabeth A Mittendorf; Gaiane M Rauch; Rosalind P Candelaria; Lei Huo; Stacy L Moulder; Jeffrey T Chang Journal: Clin Cancer Res Date: 2022-07-01 Impact factor: 13.801
Authors: Aron Gortman; Noel J Aherne; Justin Westhuyzen; Julan V Amalaseelan; Patrick M Dwyer; Matthew Hoffmann; Andrew T Last; Thomas P Shakespeare Journal: Mol Clin Oncol Date: 2021-07-01
Authors: Margaret L Axelrod; Mellissa J Nixon; Paula I Gonzalez-Ericsson; Riley E Bergman; Mark A Pilkinton; Wyatt J McDonnell; Violeta Sanchez; Susan R Opalenik; Sherene Loi; Jing Zhou; Sean Mackay; Brent N Rexer; Vandana G Abramson; Valerie M Jansen; Simon Mallal; Joshua Donaldson; Sara M Tolaney; Ian E Krop; Ana C Garrido-Castro; Jonathan D Marotti; Kevin Shee; Todd W Miller; Melinda E Sanders; Ingrid A Mayer; Roberto Salgado; Justin M Balko Journal: Clin Cancer Res Date: 2020-08-21 Impact factor: 12.531
Authors: Oluwatomi L Ladipo; Yi Ren; Keenan B Caddell; Anuyuga Sampathkumar; Chandra A Almond; Oluwadamilola M Fayanju Journal: Am J Surg Date: 2021-01-18 Impact factor: 2.565
Authors: Emily R McMullen; Stephanie L Skala; Maria E Gonzalez; Sabra Djomehri; Darshan Shimoga Chandrashekar; Sooryanarayana Varambally; Celina G Kleer Journal: Breast Cancer Date: 2020-11-27 Impact factor: 4.239
Authors: Willard Wong; Edi Brogi; Jorge S Reis-Filho; George Plitas; Mark Robson; Larry Norton; Monica Morrow; Hannah Y Wen Journal: NPJ Breast Cancer Date: 2021-07-22
Authors: Tania Rossi; Michela Palleschi; Davide Angeli; Michela Tebaldi; Giovanni Martinelli; Ivan Vannini; Maurizio Puccetti; Francesco Limarzi; Roberta Maltoni; Giulia Gallerani; Francesco Fabbri Journal: Front Med (Lausanne) Date: 2021-06-24